ProShare Advisors LLC Buys 10,531 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

ProShare Advisors LLC raised its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,114 shares of the biopharmaceutical company’s stock after acquiring an additional 10,531 shares during the quarter. ProShare Advisors LLC’s holdings in Halozyme Therapeutics were worth $2,253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Park Avenue Securities LLC lifted its holdings in shares of Halozyme Therapeutics by 6.9% during the fourth quarter. Park Avenue Securities LLC now owns 12,439 shares of the biopharmaceutical company’s stock valued at $595,000 after purchasing an additional 801 shares during the last quarter. Diversify Wealth Management LLC raised its position in Halozyme Therapeutics by 63.8% in the 4th quarter. Diversify Wealth Management LLC now owns 15,464 shares of the biopharmaceutical company’s stock worth $816,000 after buying an additional 6,025 shares during the last quarter. Diversify Advisory Services LLC raised its holdings in shares of Halozyme Therapeutics by 9.3% during the fourth quarter. Diversify Advisory Services LLC now owns 5,825 shares of the biopharmaceutical company’s stock valued at $308,000 after purchasing an additional 494 shares during the last quarter. Sugar Maple Asset Management LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter worth $373,000. Finally, Janney Montgomery Scott LLC boosted its stake in shares of Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after buying an additional 251,711 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 503 shares of the business’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now directly owns 33,108 shares in the company, valued at $2,120,567.40. This trade represents a 1.50% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,697 shares of company stock worth $1,276,552. 2.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have commented on HALO shares. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. raised their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Leerink Partners downgraded Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research note on Tuesday, May 13th. Finally, Leerink Partnrs cut shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 13th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.90.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $53.45 on Wednesday. The firm has a market capitalization of $6.59 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 0.42 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51. The company has a fifty day simple moving average of $60.39 and a 200-day simple moving average of $55.93. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Halozyme Therapeutics’s quarterly revenue was up 35.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.79 earnings per share. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.